Interpreting a Preregistered Null Result

The trial was well-powered and preregistered, so the null result is credible—no need for costly replication, redesign, or claims of “inconclusive” due to power issues. The most rigorous and cost-effective step is to quantify evidence strength directly using Ba...

The study was described as well-powered and preregistered, so power isn't the issue and pursuing a new replication or redesign would waste scarce resources without first extracting maximum information from the existing dataset. The scientifically rigorous, cos...

A well-powered preregistered study already addresses power concerns, so the priority is extracting maximal evidential value from the existing data rather than duplicating resources or abandoning the design. Bayesian reanalysis (D) directly quantifies the stren...

The trial was well-powered and preregistered, so the null result is credible—but a simple significance threshold conflates "no evidence for effect" with "evidence for no effect." Bayesian reanalysis directly quantifies the strength of evidence for the null ver...

Since the trial was well-powered and preregistered, the null result is already credible, so the key next step is to characterize the strength of evidence for the null rather than treat it as merely "not significant." Applying Bayesian analysis to the existing ...

Since the trial was well-powered and preregistered, the null result is already credible, so the priority is to characterize the strength of evidence rather than assume power problems or immediately redesign/replicate. A Bayesian reanalysis (D) directly quantif...

The trial was well-powered and preregistered, so the null result is already credible—there's no need for a further replication, redesign, or pooling before drawing conclusions. The key remaining question is how strong the evidence for the null actually is, whi...

The trial was well-powered and preregistered, so the null result is already credible—concerns about power don't apply, and immediate costly replication or redesign is premature. The most rigorous next step is to formally quantify evidential strength using Baye...

The preregistered design and adequate power make the null result credible, so the key need is to communicate how much evidence the data provide without overclaiming “no effect.” A Bayesian reanalysis can quantify support for the null versus the original hypoth...

The best choice is to report the preregistered null result transparently and avoid overinterpreting it as proof of no effect. Since the study was well-powered and preregistered, the main finding is credible, but a single null trial still does not fully establi...

Because the study was preregistered and well powered, the null finding is credible and should be reported transparently. But a single null result usually should not be treated as definitive proof of no effect; the most careful next step is to quantify how much...

The preregistered, well-powered null result is already credible, so the main task is to communicate it transparently without overstating it. A Bayesian reanalysis can add nuance by quantifying evidence for the null versus the alternative, which is especially u...

The trial was preregistered and well-powered, so the null result should be treated as credible rather than as “inconclusive” from low power. But a nonsignificant result alone does not establish the null hypothesis; a Bayesian reanalysis can directly quantify h...

The preregistered design and adequate power make the null result credible, so the main priority is to interpret it transparently without overclaiming that the effect is definitively absent. A Bayesian reanalysis can quantify how much the data support the null ...

The trial was preregistered and well-powered, so the null result is already credible and should be reported transparently rather than treated as inconclusive or replaced by post hoc changes. The most scientifically useful next step is to quantify how strongly ...

The key issue is that the trial was preregistered, well-powered, and found no significant effect, so the cleanest next step is to report the null result transparently without overinterpreting it. Because the field is biased against nulls, publishing it as prer...

To navigate this situation, the team should use Bayesian methods to quantify the strength of evidence for the null hypothesis, as a non-significant $p$-value cannot distinguish between "absence of evidence" and "evidence of absence." This approach provides a m...

This decision requires balancing the limitations of frequentist null-hypothesis testing (which cannot "prove" a null) with the high credibility of a preregistered, well-powered trial. Since the study was well-powered and preregistered, Bayesian reanalysis prov...

By using Bayesian methods, the team can move beyond the binary "significant vs. non-significant" framework to quantify whether the data actually supports the null hypothesis or is simply insensitive. This approach maximizes the value of the existing dataset wi...

The primary goal of a preregistered, well-powered trial is to provide a definitive answer to a specific scientific question, helping to counteract the field's publication bias. Utilizing Bayesian methods allows the team to move beyond binary significance thres...

Because the trial was preregistered and well-powered, the team should prioritize transparency and mitigate publication bias by publishing the primary null results as planned. Bayesian reanalysis provides a formal way to quantify strength of evidence for the nu...

This decision requires balancing the interpretation of a well-powered null result with a more informative statistical framework than traditional null-hypothesis significance testing. Since the trial was preregistered and well-powered, a Bayesian reanalysis all...

This scenario highlights the limitations of Frequentist p-values, which cannot distinguish between "absence of evidence" and "evidence of absence." Option (D) provides a methodologically rigorous path to quantify the strength of the evidence for the null hypot...

Because the trial was preregistered and well-powered, the team should prioritize transparency and avoid the pitfalls of p-hacking or publication bias. Using Bayesian reanalysis allows the team to distinguish between "absence of evidence" (inconclusive data) an...